Introduction {#bhy093s1}
============

Dopamine is involved in various cognitive processes such as reward-related processes ([@bhy093C5]; [@bhy093C21]), emotion regulation ([@bhy093C39]), and executive functions ([@bhy093C66]; [@bhy093C43]; [@bhy093C12]), via the meso-cortico-limbic pathway. This major dopaminergic pathway links the ventral tegmental area of the midbrain, the limbic system (including the ventral striatum), and the prefrontal cortex ([@bhy093C21]). Moreover, dopamine abnormalities in this pathway have been shown in multiple conditions such as major depressive disorder ([@bhy093C56]), substance-related and addictive disorder ([@bhy093C47]), schizophrenia ([@bhy093C6]; [@bhy093C41]), and in Parkinson's disease ([@bhy093C24]).

Interestingly, cognitive processes, and symptomatology of diseases involving dopamine have been shown sensitive to noninvasive brain stimulations techniques (NIBS) applied over the dorsolateral prefrontal cortex (DLPFC). Among current NIBS, transcranial direct current stimulation (tDCS) consists in applying a weak direct current between 2 electrodes, a cathode, and an anode, placed above the subject's scalp. Applied over the primary motor cortex, anodal tDCS induces excitatory effects, whereas cathodal stimulation results in inhibitory effects on motor cortex excitability. When the stimulation is applied continually during several minutes, the induced excitability changes last for up to an hour ([@bhy093C46]). From animal studies, it has been hypothesized that tDCS-mediated effects are related to a shift in neuronal resting membrane potential either toward depolarization and increased spontaneous neuronal firing at the anodal level and toward hyperpolarization and decreased firing at the cathode level ([@bhy093C4]).

As such, tDCS is a technique emerging as having procognitive effects in healthy humans ([@bhy093C38]) and a prospective therapy to decrease symptoms and improve cognition in patients with neurologic and psychiatric disorders ([@bhy093C35]; [@bhy093C36]). Specifically, bifrontal tDCS, with the anode applied over the left DLPFC coupled with the cathode placed over the right DLPFC may induce beneficial emotional and attentional processing in healthy subjects ([@bhy093C44]), as well as clinical improvements in several psychiatric conditions involving dopamine transmission abnormalities, such as major depressive disorder ([@bhy093C9]; [@bhy093C57]), substance-related and addictive disorder ([@bhy093C29]), schizophrenia with predominant negative symptoms ([@bhy093C49]), and the cognitive alterations in Parkinson's disease ([@bhy093C37]). However, contradictory studies exist putting forward the importance of the study design, the individual variability, and the brain-state dependency in the results obtained in both cognitive ([@bhy093C26]; [@bhy093C68]) and clinical studies ([@bhy093C10]; [@bhy093C40]). These discrepancies reinforce the need to better understand the spatial and temporal neurobiological effects of bifrontal tDCS. In the last decade, fMRI studies ([@bhy093C30]; [@bhy093C52]) and computational model analysis ([@bhy093C2]) highlighted subcortical effects of bifrontal tDCS reaching subcortical areas, such as dopaminergic areas. Offline studies also suggest that cortical stimulation by other NIBS approaches, such as a single session of high frequency transcranial magnetic stimulation (TMS) applied over the left DLPFC may evoke a dopamine release in the striatum ([@bhy093C62]; [@bhy093C7]). However, the effect of a bifrontal tDCS on dopamine transmission is unknown.

The aim of this study was to test, in healthy subjects in a randomized placebo-controlled double blind study, the effects of a single session of bifrontal tDCS with the anode over the left DLPFC and the cathode over the right DLPFC on the subcortical dopaminergic transmission. These effects were explored online by positron emission tomography (PET) using dopaminergic D2 subtype receptor availability via \[^11^C\]raclopride binding. We hypothesized that bifrontal tDCS can modulate subcortical dopaminergic transmission during and after the stimulation.

Methods and Materials {#bhy093s2}
=====================

Subjects {#bhy093s3}
--------

Thirty-six healthy adults were included. Exclusion criteria were smoking, history of neurological and/or psychiatric illness, medical treatments (except for oral contraceptive), contraindications to MRI or tDCS, and pregnancy. Volunteers were asked not to have caffeine on the day of scanning. Procedures were reviewed, approved by the standing ethics committee (CPP SUD EST 6, AU1148; ANSM, A01405-42) and registered on [ClinicalTrials.gov](ClinicalTrials.gov) (NCT02402101). All subjects gave written informed consent after a detailed description of the study by the recruiting psychiatrist. Subjects were compensated 100 euros. Four subjects were excluded due to technical problems (see CONSORT Flow Diagram). Thirty-two subjects (mean age = 25.25 ± 3.55 years, *n* = 16 females) completed the study.

Experimental Design {#bhy093s4}
-------------------

This study is randomized, double blind and with 2-arm parallel groups, active (*n* = 14) versus sham (*n* = 18) bifrontal tDCS (Fig. [1](#bhy093F1){ref-type="fig"}*A*). The experiment visit at the CERMEP imaging center consisted in an anatomical MRI and a PET scan during which subjects received a single tDCS session. At baseline, subjects completed personality questionnaires: Life Orientation Test-Revised (LOT-R; [@bhy093C65]), Motivation ([@bhy093C20]), Big Five Inventory ([@bhy093C54]). During the experiment visit, subjects completed before and after the PET scan a State-Trait Anxiety Inventory (STAI-YA; [@bhy093C60]) and a structured adverse effect of tDCS questionnaire ([@bhy093C8]). Blinding integrity was assessed by having subjects guess the nature of the received stimulation (active or sham). Results are provided in Table [1](#bhy093TB1){ref-type="table"}.

![(*A*) Study design. (*B*) Transcranial direct current stimulation bifrontal montage. (*C*) Hammersmith maximum probability brain atlas used as a striatal mask including the caudate nucleus, putamen, and nucleus accumbens. Abbreviations: DLPFC, Dorsolateral prefrontal cortex; tDCS, transcranial direct current stimulation.](bhy093f01){#bhy093F1}

Table 1Characteristics of subjects among the 2 groups (active and sham tDCS; mean (±SD))VariableActive tDCS (*N* = 14)Sham tDCS (*N* = 18)*P*-valueDemographic Age \[years\]24.86 (±4.05)25.56 (±3.18)0.3886 Sex \[Male:Female\]6:810:80.7216 Years of education \[years\]3.92 (±1.86)4.78 (±1.83)0.2077 Handedness \[Right:Left\]12:213:50.6278PET scan Injected dose \[MBq/kg\]320.86 (±35.02)320.33 (±59.10)0.7812 Movement translation \[mm\]−0.20 (±1.38)−0.13 (±1.79)0.2792 Movement rotation \[degrees\]0.004 (±0.011)0.004 (±0.012)0.8879Psychological assessment Motivation score123.79 (±21.00)124.06 (±15.90)0.9684 LOT-R score17.86 (±3.35)15.72 (±14.86)0.1525 BFI N score17.64 (±5.57)20.72 (±7.06)0.1781 Baseline STAI-A score25.5 (±4.07)26.61 (±5.25)0.5794 Post-tDCS STAI-A score24.71 (±4.34)26.56 (±3.49)0.1173 STAI-A score difference0.79 (±3.47)0.05 (±3.90)0.5803 Blinding \[Active:Sham:None\]6:6:25:13:00.1203[^2]

Transcranial Direct Current Stimulation {#bhy093s5}
---------------------------------------

tDCS was applied using a standard equipment (NeuroConn DC Stimulator Plus, GmbH). The anode was placed with the center of the electrode over F3 (left DLPFC) and the cathode was located over F4 (right DLPFC), according to international 10/20 EEG electrodes placement system (Fig. [1](#bhy093F1){ref-type="fig"}*B*). Electrode size was 7\*5, 35 cm^2^. tDCS (either active of sham) was delivered at rest in a single session during a dynamic PET scan. The stimulation started 40 min after the injection of the tracer, lasted 20 min, with 30 s fade in/fade out periods, and was set at 2 mA in active mode. For sham stimulation, the built-in sham mode mimicked the somatosensory artifact of active tDCS (30 s fade in/fade out, 40 s of active tDCS delivered at the beginning of stimulation).

Anatomical MRI {#bhy093s6}
--------------

All subjects underwent an anatomical MRI examination performed on a 1.5-T Magnetom scanner (Siemens), including a 3-D anatomic T1-weighted sequence covering the whole brain volume, with 1-mm^3^ cubic voxels and 176 1-mm thick slices (TR = 1970 ms, TE = 3.93 ms). This scan was done before PET scan to control subject anatomy, electrode position and was further used for spatial normalization and to define the regions of interest (ROI).

Positron Emission Tomography {#bhy093s7}
----------------------------

PET scan session always started around 10.30 a.m. During the 100-min PET acquisition, subjects were lying at rest in the machine.

### Radiochemistry {#bhy093s8}

Raclopride is a benzamide, a selective D2 receptor antagonist labeled with carbon-11, commonly used in PET studies ([@bhy093C22]). After synthesis at the CERMEP (1 synthesis per subject), \[^11^C\]raclopride was purified, formulated, and sterilized. The specific radioactivity obtained was around 3.7--18.5 GBq/μmol (100--500 mCi/μmol) at the time of injection.

### Data Acquisition {#bhy093s9}

PET scans were conducted on a Biograph mCT PET-CT tomograph (Siemens). Subjects were positioned in the scanner such that acquired planes would be parallel to the orbital-meatal line. Head movement was minimized with an airbag. A camera allowed visual control of the head's position during acquisition. Measures for tissue and head support attenuation were performed with a 1 min low-dose CT scan acquired before emission data acquisition. A bolus of \[^11^C\]raclopride (18 MBq + 2.6 MBq/kg) for 30 s followed by a constant infusion of 57% of the initial dose (i.e., 10 MBq + 1.5 MBq/kg) over 100 min, was injected through an intravenous catheter (see doses in Table [1](#bhy093TB1){ref-type="table"}). This bolus-plus-continuous-infusion method is currently used when measuring dopamine release in challenging conditions ([@bhy093C1]; [@bhy093C7]). A dynamic emission scan was acquired in list mode during the 100-min after injection. A total of 20 successive frames (5 min each) were reconstructed by using 3D-ordinary Poisson-ordered subset expectation maximization iterative algorithm incorporating point spread function and time of flight (with a Gaussian filter of 3 mm) after correction for scatter and attenuation. Reconstructed volumes consisted of 109 contiguous slices (2.03-mm thickness) of 128 × 128 voxels (2.12 × 2.12 mm^2^). Actual resolutions for reconstructed images were approximately 2.6 mm in full width at half maximum in the axial direction and 3.1 mm in full width at half maximum in the transaxial direction measured for a source located 1 cm from the field of view ([@bhy093C28]).

Data Preprocessing and Binding Parametric Imaging {#bhy093s10}
-------------------------------------------------

All preprocessing were carried out by a single individual blind to group status (active or sham). For each subject, preprocessing of MRI and PET data was done using an in-house script combining functions of Statistical Parametric Mapping 12 (SPM12, Wellcome Trust Centre of Neuroimaging), the MINC Tool Kit (Mc Connell brain Imaging centre, McGill University), and the Turku PET analysis software (Turku PET Centre). PET dynamic was corrected for between-frame motion with a 3-D rigid body model using SPM12. This realigned dynamic PET scan was used hereon out. T1 was coregistered to the mean PET image for each subject and then spatially normalized into standard MNI space (Montreal Neurological Institute/International Consortium for Brain Mapping stereotactic space) with the "segment" function of SPM12. This step provided a classification of the T1 MRI into 6 tissue classes and generation of MNI to subject space deformation fields. The atlas was then back normalized into the subject space, and combined with the gray matter image. The assessment of free and nonspecific \[^11^C\]raclopride ligand kinetics was based on the time--activity curve of a reference region (i.e., the cerebellum, without vermis) devoid of specific dopamine D2-like receptors ([@bhy093C53]). Thus, extracellular dopamine concentration was assessed using simple pseudo-equilibrium 5 min ratios of ROI (striatum) to cerebellum activities (BP~R~), computed with the "imgratio" function of the Turku PET library. BP~R~ images were spatially normalized into the standard MNI space and smoothed using an isotropic 8-mm full width half maximum Gaussian kernel. ROIs were selected from the Hammersmith maximum probability brain atlas ([@bhy093C23]; [@bhy093C19]). The a priori ROI used in this study is the striatum. This ROI was used for subsequent regional BP~R~ and used as mask in the SPM analysis. The anatomical subparts of the striatum (i.e., caudate nucleus, putamen, and nucleus accumbens; Fig. [1](#bhy093F1){ref-type="fig"}*C*) were used only after the analysis to name the significant clusters accordingly.

Statistical Analyses {#bhy093s11}
--------------------

A voxel-based SPM analysis was performed, using a flexible factorial design based on repeated measures ANOVA, to assess the effect of active tDCS compared with sham tDCS on BP~R~ for each time period: baseline period (30--40 min), stimulation period (45--60 min, effects during stimulation), Post1 period (65--80 min, acute after-effects), and Post2 period (80--95 min, subsequent after-effects). This analysis was restricted to voxels belonging to the striatum mask (a priori ROI). In SPM12, used in the present study, contrasts (post hoc) can be performed only when the omnibus ANOVA created with the model is significant ([@bhy093C18]). Post hoc Student *t*-score (SPM-{*t*}) maps were computed to elucidate the increase or decrease of \[^11^C\]raclopride uptake during (Stimulation time period) or after (Post1 and Post2 time periods) tDCS, by comparing active and sham groups. The following contrasts were computed: \[(Stimulation--Baseline)~sham~ vs. (Stimulation−Baseline)~active~\], \[(Post1−Baseline)~sham~ vs. (Post1−Baseline)~active~\], \[(Post2−Baseline)~sham~ vs. (Post2−Baseline)~active~\], \[((Post1 + Post2)−Baseline)~sham~ vs. ((Post1 + Post2)−Baseline)~active~\], \[((Stimulation + Post1 + Post2)−Baseline)~sham~ vs. ((Stimulation + Post1 + Post2)−Baseline)~active~\], \[(Post1−Stimulation)~sham~ vs. (Post1−Stimulation)~active~\], \[(Post2−Stimulation)~sham~ vs. (Post2− Stimulation)~active~\], \[(Post1−Post2)~sham~ vs. (Post1−Post2)~active~\], \[((Post1 + Post2)−Stimulation)~sham~ vs. ((Post1 + Post2)−Stimulation)~active~\]. SPM maps were thresholded at *P*~uncorr~ \< 0.001 at the voxel level, with a minimum of 10 contiguous voxels (80 mm^3^), which is the expected number of voxels per cluster in the 3D gaussian space. Then, only clusters with *P*~FWE~ \< 0.05 (SPM family wised error correction for multiple comparisons) at the cluster level were considered significant. Reported coordinates (Table [2](#bhy093TB2){ref-type="table"}) conform to the MNI space, for each cluster. Time--activity curves were extracted for each cluster and the BP~R~ value computed in each time period and for each group. BP~R~ were also expressed as the relative difference between groups at each time periods (Table [3](#bhy093TB3){ref-type="table"}). A secondary analysis was performed in order to investigate the potential impact of dopamine baseline levels (BP~R~) on the relative changes (Delta (%)) observed in the significant cluster, with a correlation analysis (Pearson\'s *r* correlation coefficient). *P* \< 0.05 was considered significant. Demographic and clinical characteristics were examined using descriptive statistics. Normality was assessed by the Shapiro--Wilk test. Statistical analyses were done between groups using the Welch 2 sample *t*-test (Injected dose/kg, Years of education, Motivation score, LOT-R score, BFI N score, STAI-difference, BP~R~ baseline) or the Wilcoxon rank sum test with continuity correction (age, STAI-A scores baseline and post, movement translation) and the Chi-squared test for handedness, sex variables, and blinding integrity. These analyses were done using in-house scripts in R (<https://cran.r-project.org/>). Table 2Parametric analysis: group comparisonMNI coordinates (mm)ClusterContrast/region*xyzz*-Score*P*~FWE~Volume (mm^3^)(Stimulation + Post1 + Post2)−Baseline right caudate nucleus101444.060.037272(Post1 + Post2)−Baseline Right caudate nucleus101444.280.023352(Post1 + Post2)−Stimulation Right caudate nucleus616−43.490.092144 Left putamen−282−23.650.081160Post1−Stimulation Right caudate and accumbens nuclei612−44.170.092144 Left putamen−302−63.530.064192Post2−Baseline Right caudate nucleus101444.400.022360 Left putamen−2210−123.470.105128Post2−Stimulation Right caudate nucleus101423.630.105128[^3]Table 3\[^11^C\]raclopride binding potential ratio in clustersRaclopride BP~R~, mean (±SD)Cluster volume (mm^3^)/tDCS groupCondition 1Condition 2Relative variation, %Difference Active---Sham GroupRight caudate nucleus 272BaselineStimulation + Post1 + Post2−22.46Active tDCS5.78 (±0.88)4.89 (±1.40)−15.05 (±9.47)Sham tDCS4.93 (±1.01)5.23 (±1.48)7.41 (±14.79) 352BaselinePost1 + Post2−25.36Active tDCS5.66 (±0.83)4.55 (±1.28)−19.05 (±9.86)Sham tDCS4.78 (±0.91)5.02 (±1.39)6.31 (±15.57) 144StimulationPost1 + Post2−20.33Active tDCS4.77 (±1.19)4.18 (±1.74)−11.73 (±21.18)Sham tDCS4.46 (±1.49)4.84 (±2.05)8.60 (±15.48) 144StimulationPost1−33.82Active tDCS3.99 (±1.30)3.39 (±1.43)−13.34 (±18.71)Sham tDCS3.35 (±1.09)3.94 (±1.57)20.48 (±26.03) 360BaselinePost2−31.97Active tDCS5.64 (±0.92)4.31 (±1.36)−23.32 (±12.03)Sham tDCS4.82 (±0.89)5.16 (±1.55)8.65 (±19.90) 128StimulationPost2−29.32Active tDCS5.64 (±1.47)4.52 (±2.04)−19.02 (±25.83)Sham tDCS5.00 (±1.62)5.47 (±2.45)10.30 (±22.03)Left putamen 160StimulationPost1 + Post2−16.49Active tDCS7.91 (±2.13)6.58 (±2.00)−13.89 (±18.07)Sham tDCS6.81 (±2.03)6.80 (±1.88)2.60 (±19.96) 192StimulationPost1−13.99Active tDCS6.86 (±1.53)5.78 (±1.52)−13.99 (±21.78)Sham tDCS6.04 (±1.39)6.00 (±1.55)−0.00 (±18.03) 128BaselinePost2−25.9Active tDCS4.89 (±0.94)4.44 (±2.13)−6.95 (±25.21)Sham tDCS4.43 (±0.86)5.28 (±2.10)18.95 (±23.71)[^4]

Data and Code Availability {#bhy093s12}
--------------------------

The data and custom-written analysis code that support the findings of this study are available on request from the corresponding author.

Results {#bhy093s13}
=======

Subjects' Characteristics {#bhy093s14}
-------------------------

The subjects' characteristics are shown in Table [1](#bhy093TB1){ref-type="table"} for both active and sham tDCS groups. No statistical differences were found between the 2 groups. As no distribution differences between groups (gender and age) were observed, we did not use them as covariables for the statistical calculations. No adverse effects were reported either due to the tDCS stimulation, the MRI, or the PET scans.

Kinetic Analysis {#bhy093s15}
----------------

The extraction of the \[^11^C\]raclopride binding potential ratio (BP~R~) in the region of interest (striatum) (Fig. [2](#bhy093F2){ref-type="fig"}*A*) enabled us to determine a baseline time period during which BP~R~ reached a state close to equilibrium. The other time periods, that have been be used to create the mean ratio images for the parametric analysis, were of 15 min each. Thus, the effects of the stimulation have been examined over 4 time periods: Baseline period (30--40 min after tracer injection), Stimulation period (45--60 min, effects during stimulation), Post1 period (65--80 min, acute after-effects), Post2 period (80--95 min, subsequent after-effects). A baseline BP~R~ difference between the active and sham group in the striatum was reported (*P* = 0.018; Active 5.23 ± 0.51; Sham: 4.79 ± 0.46; mean ± SD). Therefore, subsequent analysis took this difference into account with comparisons of relative variations in each contrast.

![(*A*) Kinetic analysis. (i) Time--activity curve in the striatum and the cerebellum (ii) Binding potential ratio in the striatum; for both groups across the 20 PET frames (5 min per frame). (*B*) Parametric analysis---Subsequent after-effects of the stimulation in different clusters when comparing the baseline period to the Post2 period (*P*~uncorr~ \< 0.001 at the voxel level, with a minimum of 10 contiguous voxels (80-mm^3^)). For the significant cluster (*P*~FWE~ \< 0.05 at the cluster level), the BP~R~ kinetic curves for both groups across the 20 PET frames (5 min per frame) are extracted and are expressed as BP~R~ ratio (% of baseline). The anatomical subparts of the striatum (i.e., caudate nucleus, putamen, and nucleus accumbens) were named based on the Hammersmith maximum probability brain atlas. Abbreviations: Bas., Baseline period; Stim, Stimulation period; Red curve, Active tDCS; Blue curve, Sham tDCS, BP~R~, Binding Potential Ratio; TACs, Time--Activity Curves.](bhy093f02){#bhy093F2}

Parametric Analysis {#bhy093s16}
-------------------

The analysis was performed using a mask of the whole striatum (a priori ROI). The voxel-based analysis showed significant clusters in the striatum when comparing the time periods determined between groups (Table [2](#bhy093TB2){ref-type="table"}). More specifically, when comparing active and sham tDCS groups, areas of significant changes in dopaminergic activity showed BP~R~ decreases in the striatum (Fig. [2](#bhy093F2){ref-type="fig"}*B*). After the complete analysis, the position of the significant clusters have been identified according to the anatomical subparts of the striatum delineation of Hammersmith maximum probability brain atlas, that is, the caudate nucleus, putamen, and nucleus accumbens. The \[^11^C\]raclopride BP~R~ in clusters and their relative difference in the active tDCS group compared with the sham group are summarized in Table [3](#bhy093TB3){ref-type="table"}.

### Effects of tDCS During the Stimulation (Stimulation Period) {#bhy093s17}

No significant differences in BP~R~ were observed in the striatum when comparing stimulation and baseline periods, between groups \[(Stimulation−Baseline)~sham~ vs. (Stimulation−Baseline)~active~\].

### After-Effects of tDCS {#bhy093s18}

#### During the 5--35-min period following the stimulation (Post1 + Post2 period) {#bhy093s180}

Significant differences in BP~R~ were reported in the active group compared with sham group when comparing the baseline period with the 5--35-min period following the stimulation \[((Post1 + Post2)−Baseline)~sham~ vs. ((Post1 + Post2)−Baseline)~active~\], specifically in the right caudate nucleus (−25.4%). Accordingly, a trend towards significance was also reported when comparing the stimulation period with the 5--35-min period following the stimulation \[((Post1 + Post2)−Stimulation)~sham~ vs. ((Post1 + Post2)− Stimulation)~active~\], specifically in the left putamen (−16.5%) and in the right caudate nucleus (−20.3%).

#### Acute after-effects: during the 5--20-min period following the stimulation (Post1 period) {#bhy093s181}

No significant differences in BP~R~ were observed between groups in the striatum when comparing the baseline period with the 5--20-min period immediately following the stimulation \[(Post1−Baseline)~sham~ vs. (Post1−Baseline)~active~\].

However, when comparing the 5--20 min period immediately following the stimulation to the stimulation period \[(Post1− Stimulation)~sham~ vs. (Post1−Stimulation)~active~\], a trend towards a significant BP~R~ decrease was observed in the active group compared with sham group specifically in the left putamen (−14.0%) and in the right accumbens and caudate nuclei (−33.8%).

#### Subsequent after-effects: during the 20--35-min period following the stimulation (Post2 period) Figure [2](#bhy093F2){ref-type="fig"}*B* {#bhy093s182}

Differences in BP~R~ were reported in the active group compared with sham group when comparing the baseline period with the 20--35-min period following the stimulation \[(Post2−Baseline)~sham~ vs. (Post2−Baseline)~active~\], specifically significant in the right caudate nucleus (−32.0%) and trending significance in the left putamen (−25.9%). Furthermore, a trend towards a significant differences was reported specifically in the right caudate nucleus (−29.3%) when comparing the stimulation period with the 20--35-min period following the stimulation \[(Post2−Stimulation)~sham~ vs. (Post2−Stimulation)~active~\].

Correlation Analysis {#bhy093s19}
--------------------

An analysis was performed in the cluster reported significant with the voxel-based parametric analysis, that is, in the right caudate nucleus, to investigate the impact of baseline dopamine BP~R~ levels on the relative BP~R~ difference (Delta (%)) between Post2 and Baseline time periods. This correlation analysis was not significant (active group: *r* = 0.26, *P* = 0.37; sham group: *r* = 0.45, *P* = 0.061) ([Supplementary Fig. 1](#sup1){ref-type="supplementary-material"}).

Discussion {#bhy093s20}
==========

Here, we present the first direct evidence of temporally and spatially distributed effects of bifrontal tDCS on dopamine transmission in the striatum after one session of 20 min at 2 mA, in healthy subjects. These results provide the first proof of a decrease in \[^11^C\]raclopride BP~R~ suggesting an increase in extracellular dopamine induced by a dopamine release evoked by a tDCS session.

The impact on dopamine transmission seems progressive during the stimulation and reaches significance during the 5--35-min period following the end of stimulation. The absence of significant effects during the stimulation could be considered as contrasting with some previous online stimulation studies. In this line, glutamate/glutamine variations have been observed in the left striatum during a single bifrontal tDCS session using online MRS ([@bhy093C25]). The discrepancy with our results could be explained by several factors. First, regarding technical features, MRS measures a mixture of compounds involved in neurotransmission and metabolism in every cellular compartment of the voxel. Here, with \[^11^C\]raclopride PET, we addressed dopamine neurotransmission in terms of extracellular dopamine. Second, regarding physiological features, it cannot be ruled out that the time-scale of glutamate and dopamine variations is different. With this hypothesis, changes in the macro- and microenvironment induced during tDCS could trigger dopamine release only when the stimulation ends. Another explanation could be a matter of significant threshold. Indeed, the BP~R~ curve over time (Fig. [2](#bhy093F2){ref-type="fig"}*B*) shows a continuous decrease starting at the beginning of the stimulation, only for the active tDCS group. However, this decrease reaches significance only after the end of the stimulation compared with the sham group.

The increase in dopamine is in line with studies exploring TMS impact on dopamine transmission in animals, healthy subjects and in pathological conditions, as well as tDCS in animals ([@bhy093C31]). These studies conducted offline showed modulations of dopamine transmission in the striatum after stimulation protocols applied over the prefrontal cortex. For example, an increase in extracellular dopamine specifically in the left dorsal caudate nucleus was shown after a repetitive TMS stimulation with the coil over the left DLPFC ([@bhy093C62]). In the same line, an animal tDCS study reported an increase in dopamine concentration in rat basal ganglia after cathodal tDCS compared with sham and anodal conditions. The effect was significant from 120 min after the stimulation ([@bhy093C64]).

The significant clusters identified in our study are localized specifically in the ventral regions of the striatum. This spatially distributed after-effect of bifrontal tDCS is supported by the notion that complex organized behavior is made possible by the connectivity between several striato-thalamo-cortical circuits, including distinct striatal and cortical regions ([@bhy093C21]). Several studies have highlighted the model of a tripartite division of the striatum ([@bhy093C55]; [@bhy093C14]; [@bhy093C15]; [@bhy093C50]), using noninvasive neuroimaging methods. This striatal parcellation corresponds to 3 functionally distinct regions: a motor region which includes the dorsal part of the putamen and caudate nucleus, a cognitive region including the ventral rostral putamen, dorsal caudate, superior ventral striatum corresponding to the ventral caudate, and an affective region composed of the inferior ventral striatum or nucleus accumbens. In addition, connectivity studies have traced the structural and functional coupling between individual striatal and cortical regions and have shown that the DLPFC projects extensively to the ventral striatum, an overlap between regions involved in affective and cognitive processes, corresponding to the reward--motivation network. According to these studies, our clusters are located in the cognitive and affective regions of the striatum, regions anatomically linked to the DLPFC targeted by the tDCS montage.

Our findings of an increase in extracellular dopamine spatially located in the ventral striatum, obtained after a single session of bifrontal tDCS, are in line with the possible procognitive effects seen after frontal tDCS in healthy subjects and in pathological conditions ([@bhy093C33]; [@bhy093C36]). Indeed, multiple studies focused on the reciprocal influence of cognitive functions and variations in dopamine. Imaging studies have detected increases in ventral striatal extracellular dopamine concentrations during task components such as motor learning and execution, reward-related processes, stress, and cognitive performance ([@bhy093C16]). Moreover, predictions about anticipated future rewarding have been shown to be encoded by dopamine concentration of the ventral striatum, and that the amount of dopamine itself encodes the distance from the reward ([@bhy093C27]). In the same line, manipulations that enhance dopamine transmission, such as addictive drugs and dopamine agonists, often act as neuroenhancers ([@bhy093C66]; [@bhy093C47]). However, as with pharmacological neuroenhancers, tDCS could also be linked to a direct dopamine release within the prefrontal cortex. We acknowledge that our study did not allow for an evaluation of the tDCS effects on dopamine release in the prefrontal cortex. Using a high affinity radioligand (\[^11^C\]FLB-457), [@bhy093C11]) have shown that TMS over the left DLPFC induces a reduction of BP in the ipsilateral pre- and subgenual anterior cingulate cortex, and medial orbitofrontal cortex. Further studies are needed to evaluate the direct effect of tDCS on the prefrontal cortex.

The significant after-effects of bifrontal tDCS beg the question of possible mechanisms leading to the dopamine release in the striatum. The literature supports 2 possible mechanisms, involving glutamatergic cortical projections: a direct pathway, via corticostriatal projections and an indirect pathway, involving cortical projections on mesostriatal dopamine neurons in the midbrain. Both mechanisms could be involved in tDCS effects, according to animal studies showing that stimulation of the PFC could promote activation in both striatal and ventral tegmental regions ([@bhy093C63]; [@bhy093C51]). With the notion that tDCS modulates glutamatergic and GABAergic activity under the electrodes ([@bhy093C61]), bifrontal tDCS may impact the glutamatergic projections from the DLPFC, and consequently modify subcortical activity, as shown by a recent MR-spectroscopy study reporting that bifrontal tDCS had fast excitatory effects in the left striatum ([@bhy093C25]). To further investigate the exact mechanism, future studies could explore the impact of bifrontal tDCS on the relation between blood flow and dopamine transmission variations.

Based on our results and according to the increasing use of tDCS in various populations, the level of dopamine signaling should be considered for each tDCS application. Indeed, it is important to note that the subject's brain-state at the time of stimulation plays an important role in the response ([@bhy093C59]). Accordingly, effects of bifrontal tDCS could be sensitive to the level of dopamine activity at baseline. An inverted U-shape hypothesis has been put forth describing a nonlinear relationship between cognitive performance and dopamine concentration. Both too high as well as too low concentrations of dopamine are associated with suboptimal cognitive processing ([@bhy093C13]). Pharmacological studies suggest a similar relationship between dopaminergic activity and neuroplastic changes induced by tDCS applied over the human motor cortex ([@bhy093C34]; [@bhy093C45]; [@bhy093C17]). A recent review has reported that the modulation of dopamine D1 and D2 signaling by agonist and antagonist administration has a significant dose and receptor-dependent impact on tDCS after-effects ([@bhy093C42]). Combined with our results, a reciprocal interaction between dopaminergic systems and tDCS can be suggested.

Therefore, exploring the effects of bifrontal tDCS under conditions where basal dopamine activity is altered could be of major relevance. First, in psychiatric conditions such as depression, stimulation studies robustly report groups of responders and nonresponders to repeated bifrontal tDCS while physiological levels of dopamine activity have been shown heterogeneous across subjects ([@bhy093C58]). According to our results, it can be hypothesized that the basal dopamine activity level or the change in extracellular dopamine evoked by a first bifrontal tDCS session could be a predictive marker of the therapeutic response obtained after applying multiple tDCS sessions on several days, protocol used in studies developing tDCS as a treatment for psychiatric disorders. Second, tDCS devices are being increasingly used in a recreational manner with little or no warning to interaction with medication or psycho-stimulant, in particular those interacting with the dopamine transmission. However in our study, we did not observe any impact of the baseline dopamine levels on the release induced by tDCS. Nevertheless, our study included only healthy subjects at rest and free of treatment interfering with dopaminergic transmission. From this, it could be suggested that, in these specific population and conditions, the intersubjects difference in dopamine activity may not impact tDCS effects. Overall, our work shows the ongoing importance of controlled studies when using tDCS and should boost the research in this field to prevent the unsafe use of tDCS in uninformed people.

One limitation of this study is that PET results were not associated with behavioral findings (e.g., improvement of working memory performances), hence no procognitive effects were in fact inspected in the present study. The second limitation is that dopamine has also been shown to be involved in placebo responsiveness ([@bhy093C3]). The placebo-controlled study design developed here overcame in part this problem. Moreover, the psychological assessment conducted did not reveal differences between active and sham groups regarding personality traits, motivation, and anxiety.

To conclude, the present study provides first direct evidence that bifrontal tDCS induces neurotransmitter release in polysynaptic connected subcortical areas. Our findings offer new insights for innovative use of tDCS as a therapeutic solution in neuropsychiatric conditions involving dopamine transmission impairments in the reward--motivation network. In the context of the ongoing debate surrounding tDCS in the literature and beyond the simple "excitatory--inhibitory" model, levels of dopamine activity and reactivity should be a new element of the mosaic, adding to other parameters such as individual head anatomy variability, electrode position, and brain-state dependency for a general hypothesis of brain modulation by bifrontal tDCS ([@bhy093C32]; [@bhy093C48]; [@bhy093C67]).
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[^3]: Clusters of the parametric analysis. Effect of tDCS in the striatum using a flexible factorial design (time periods\*groups). SPM maps were thresholded at *P*~uncorr~ \< 0.001 at the voxel level, with a minimum of 10 contiguous voxels (80 mm^3^). Only clusters with *P*~FWE~ \< 0.05 at the cluster level were considered significant. We also reported the *z*-score at the peak level. The contrast reported here are \[Active tDCS \< Sham tDCS\]. No significant clusters were reported with the contrast \[Active tDCS \> Sham tDCS\]. The anatomical subparts of the striatum (i.e., caudate nucleus, putamen, and nucleus accumbens) were named based on the Hammersmith maximum probability brain atlas.

[^4]: \[^11^C\]raclopride binding potential in clusters revealed by the parametric analysis---BP~R~ variations during and after the stimulation compared with baseline (relative variation, %). The anatomical subparts of the striatum (i.e., caudate nucleus, putamen, and nucleus accumbens) were named based on the Hammersmith maximum probability brain atlas.
